Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus.
To evaluate the relationship between laboratory markers of HIV, AIDS-defining events, study discontinuation, and summary scores from the MOS-HIV Health Survey. Secondary analysis of data from a clinical trial of antiretroviral therapies in advanced HIV-infected patients (N = 940). Clinical and health-related quality-of-life data were collected over 48 weeks. Linear regression, logistic regression and survival analyses were performed to evaluate the relationships between MOS-HIV summary scores, clinical events, and laboratory markers. Each point increase in PHS resulted in a 3.0% decrease in the likelihood of developing an AIDS-defining event (p < .05) and a 2.7% decrease in likelihood of study discontinuation (p < .05). MHS did not significantly predict clinical events, but did predict study discontinuation (p < .05). From the linear regression analyses, the change in CD4 counts was a significant predictor of the change in MHS (p < .01). The MOS-HIV summary scores predict clinical events and study discontinuation in advanced HIV-infected patients.